Accurate and integral cellular DNA replication is modulated by multiple replication‐
associated proteins, which is fundamental to preserve genome stability. Furthermore …

Olaparib (Lynparza®) is a poly (adenosine diphosphate-ribose) polymerase (PARP)
inhibitor approved for first-line maintenance treatment in adults with advanced ovarian …

Despite the promising activity of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) in
many cancer types with defects in the DNA damage response the majority of the treated …

7-Methylguanine (7-MG), a natural compound that inhibits DNA repair enzyme poly (ADP-
ribose) polymerase 1 (PARP-1), can be considered as a potential anticancer drug …

Poly (adenosine diphosphate [ADP]–ribose) polymerases inhibitors (PARPi), the first
clinically approved drug that exhibits synthetic lethality, are moving to the forefront of cancer …

Unfortunately, ovarian cancer is still diagnosed most often only in an advanced stage and is
also the most lethal gynecological cancer. Another problem is the fact that treated patients …

In this study, we investigated the formulation of stable solid dispersions to enhance the
bioavailability of olaparib (OLA), a therapeutic agent for ovarian cancer and breast cancer …

Objective To evaluate the effect of secondary cytoreductive surgery (SeCRS) followed by
platinum-based chemotherapy (PBC) and olaparib tablets as maintenance therapy in …

Background and purposes The pathogenic BRCA1/2 germline mutations contributed to
Hereditary Breast and Ovarian Cancer (HBOC) susceptibility. The features of BRCA1/2 …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors theoretically promote synthetic
lethality in cancer cells with homologous recombination deficiency (HRD). However, clinical …